Jamie Kang

[Seminars in Immunology] Scientists discuss how ferroptosis shapes immune responses in pancreatitis and pancreatic cancer and examine the factors that determine whether it promotes inflammation, antitumor immunity, or immune tolerance.

[Revolution Medicines, Inc.] Revolution Medicines, Inc. announced that the US FDA accepted for review the company’s New Drug Application for daraxonrasib, an oral RAS(ON) multi-selective inhibitor, for previously treated metastatic PDAC.

[Proceedings of the National Academy of Sciences of the United States of America] Investigators demonstrated continued dependency on ERG in metastatic prostate cancer and identify a druggable pocket within its N-terminal Pointed (PNT) domain.

[Proceedings of the National Academy of Sciences of the United States of America] Researchers identified ZNF263 as a transcriptional repressor that silences MHC-I by recruiting nucleosome-remodeling and deacetylase (NuRD) to the STAT1 promoter, reducing STAT1 and MHC-I expression.

[Journal for Immunotherapy of Cancer] Scientists hypothesized that the addition of stereotactic body radiation therapy could enhance immune responses and improve treatment outcomes.

[Cancer Letters] The authors functionally characterized a novel docetaxel resistance-associated lncRNA in prostate cancer. They identified an uncharacterized lncRNA, termed HUDRPC, which was significantly upregulated in resistant cells and patient-derived tumor tissues.